BioCentury
ARTICLE | Clinical News

Imbruvica, Gazyva combo reduces disease progression or death by 77% in Phase III for first-line CLL

January 4, 2019 5:08 AM UTC

AbbVie Inc. (NYSE:ABBV) reported additional data from the Phase III iLLUMINATE (PCYC-1130) trial to treat previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) showing that Imbruvica ibrutinib plus Gazyva obinutuzumab reduced the risk of disease progression or death by 77% at a median follow-up of 31.3 months vs. chlorambucil plus Gazyva (median not reached vs. 19 months, HR=0.23, 95% CI: 0.15, 0.37, p<0.0001). Data were presented at the American Society of Hematology (ASH) meeting in San Diego and published in The Lancet Oncology.

AbbVie previously reported that Imbruvica plus Gazyva met iLLUMINATE's primary endpoint of improving progression-free survival (PFS) vs. chlorambucil plus Gazyva, but did not disclose detailed data. The open-label, international trial enrolled 229 newly diagnosed CLL patients. PFS was assessed by an independent review committee (see "Imbruvica, Gazyva Combo Meets in Phase III for First-Line CLL")...